Osanni Bio, a development-stage therapeutics platform reinventing discovery and development of new medicines, announced the close of a $190 million Series B financing. The round was led by Patient Square Capital, a leading health care investment firm, with participation by existing investors the Horowitz Group, Invus Opportunities, and the Retinal Degeneration Fund.